Pluristem Issued U.S. Patent 'Adherent Cells From Placenta Tissue and Use Thereof in Therapy'

Pluristem Therapeutics Inc.

today announced that the U.S. Patent and Trademark Office has issued to the Company patent #9,096,827 titled "Adherent Cells From Placenta Tissue and Use Thereof in Therapy". The patent protects specific methods of culturing placental adherent stromal cells, and use of these cells for the treatment of a wide variety of diseases. Indications covered by the patent include a wide range of ischemic conditions such as heart disease, stroke, peripheral arterial disease (which includes critical limb ischemia and intermittent claudication), graft-versus-host disease, solid organ transplantation, hematopoietic stem cell transplantation, diabetes, autoimmune diseases, neuropathic pain and cancer. "The U.S. is a very significant market for us and the protection of our IP in this market is a top priority for us. We are pleased to have been granted this patent covering both manufacturing methods and treatment indications. This patent contribute to our IP position we are building in the USA to support our clinical development strategy and future manufacturing and marketing in the USA," stated Pluristem CEO Zami Aberman. Pluristem has been issued over 40 patents worldwide, and has approximately 150 more